Genitourinary Cancers Symposium

Darolutamide With Radiation Therapy Under Clinical Trial Investigation in Intermediate-Risk Prostate Cancer

February 18, 2020

In an interview with Targeted Oncology, Martin T. King, MD, PhD,discusses INTREPId following his poster presentation of the trial design at the 2020 Genitourinary Cancer Symposium. He also discusses other another promising studies being presented at the conference.

Patients With Metastatic RCC Receive TKIs or mTOR Inhibitors After Immunotherapy

February 18, 2020

Most patients with metastatic renal cell carcinoma whose disease progresses after immunotherapy given either alone or in combination with other agents receive subsequent treatment with VEGF tyrosine kinase inhibitors or mTOR inhibitors. When administered post-immunotherapy, cabozantinib is associated with superior median progression free survival, according to retrospective data from a real-world study of patients treated at 16 Italian referral centers.

Effects of SBRT Plus Nivolumab Result in Responses for Certain RCC Subgroups

February 17, 2020

Stereotactic body radiotherapy combined with nivolumab was associated with “high” disease control and overall survival rates in a phase II study of pretreated patients with metastatic renal cell carcinoma, according to lead investigator Cristina Masini, MD, who presented the data at the 2020 Genitourinary Cancers Symposium.

Nivolumab Plus Sitravatinib Combo Impresses in Renal Cell Carcinoma

February 17, 2020

Combining a broad-spectrum tyrosine kinase inhibitor with an immune checkpoint inhibitor resulted in a high disease control rate in a preliminary dose-finding trial involving patients with advanced clear cell renal cell carcinoma.

MK-6482 Active in Advanced Clear Cell RCC

February 16, 2020

A fourth of patients with advanced clear cell renal cell carcinoma responded to single-agent therapy with an oral hypoxia-inducible factor–2α inhibitor, which achieved a disease control rate of 80%, a preliminary clinical trial showed.

Neoadjuvant Nivolumab Plus Chemotherapy Results in High Response Rates in Muscle-Invasive Bladder Cancer

February 15, 2020

Nivolumab plus gemcitabine and cisplatin administered in the neoadjuvant setting to patients with muscle-invasive bladder cancer resulted in a pathologic nonmuscle-invasive rate of 66% and a pathologic complete response rate of 49%.

Potential With Cabozantinib Plus Nivolumab in Advanced RCC

February 15, 2020

Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, senior physician, instructor in medicine, Harvard Medical School, discusses the goals of the phase III CheckMate-9ER trial, which is evaluating cabozantinib combined with nivolumab in previously untreated patients with advanced or metastatic renal cell carcinoma (RCC).

Durvalumab Plus Olaparib Combo Shows 50% Pathologic Complete Response in MIBC

February 15, 2020

The combination of durvalumab and olaparib may have activity as neoadjuvant therapy in the treatment of muscle-invasive bladder carcinoma.

Second-Line Immunotherapy Combos in MORPHEUS Trial for Advanced Urothelial Carcinoma

February 15, 2020

Alexandra Drakaki, MD, assistant professor of medicine, hematology, and oncology, University of California, Los Angeles, discusses the goals of the phase Ib/II MORPHEUS trial, which is an umbrella study evaluating several second-line immunotherapy combinations in patients with advanced or metastatic urothelial carcinoma.

Apalutamide Reduces Rate of Second Progression in Men With mCSPC

February 14, 2020

Apalutamide plus androgen deprivation therapy reduced the risk of second progression or death regardless of hormonal or taxane therapy as the first subsequent life-prolonging therapy in patients with metastatic castration-sensitive prostate cancer.